Why WELL Health (TSX:WELL) Stock Has Soared 20% Over the Past Month

The recent acquisitions and potential listing on NASDAQ have sent the share price of WELL Health Technologies (TSX:WELL) soaring over the past month.

| More on:
healthcare pharma

Image source: Getty Images

Shares of WELL Health Technologies (TSX:WELL) have soared nearly 20% during the past month.

The stock closed at $6.73 on May 13. As of this writing, shares are trading at $8.04, representing a gain of 19.47%.

Vancouver-based WELL focuses on consolidating and modernizing clinical and digital assets within the primary healthcare sector.

First-quarter results

Led by its software and services revenue, WELL reported record-breaking revenue of $25.6 million in the first quarter of 2021, reflecting a 150% year-over-year increase. The $7.6 million contribution from software and services increased by 345% compared to the same quarter in the prior year.

These latest results marked the second quarter in a row that WELL has achieved positive adjusted EBITDA. Adjusted EBITDA was $0.5 million for the quarter compared to a loss of $0.2 million for the same period in 2020.

The company reported record adjusted gross profit of $10 million, which represents 155% year-over-year growth. WELL’s adjusted gross margin percentage rose slightly to 39.3% during the quarter.

Aggressive acquisition strategy

In April, the company completed its acquisition of CRH Medical. CRH provides products and services for the treatment of gastrointestinal diseases throughout the United States. One of the company’s most well-known products, the O’Regan System, is widely used by gastroenterologists.

Previously listed on the NYSE and TSX stock exchanges, CRH Medical became WELL’s seventh business unit.

According to Hamed Shahbazi, chairman and CEO, WELL is aggressively focused on acquiring companies to generate free cash flow. Shahbazi said, “CRH accelerates our revenue growth and significantly boosts our free cash flow, which will be used to make additional cash flow generating acquisitions. I am also pleased to report that CRH, now operating as a stand-alone WELL business unit, is on track to meet its business plan goals to generate over US$150M in revenues and over US$40M in free cashflow before leverage and tax costs.”

Earlier this week, Shahbazi announced that WELL has sealed a deal to acquire MyHealth for $206 million. According to Shahbazi’s tweet, this deal makes WELL Health “…the largest owner-operator of outpatient medical clinics and the leading multi-disciplinary telehealth service provider in Canada.”

IPO listing on NASDAQ

During the earnings call, WELL hinted that it may soon be listing in the U.S. on the NASDAQ exchange. During the call, the company disclosed its engagement with renowned law firm Fenwick & West to help it with a U.S. IPO listing in the fourth quarter of 2021.

Fenwick is well known in the investment world. The company’s client base includes high-profile names such as Facebook, Amazon, and Cisco. More recently, Fenwick was involved in the IPO listing of Coinbase.

The bottom line

So far during 2020, WELL has gained 500% in market value. Much of this increase can be attributed to the growing adoption of WELL’s virtual healthcare and medical data services, especially during the pandemic.

The company’s recent announcements of acquisitions and investor speculation of a listing on NASDAQ have helped send its share price soaring, especially over the past month.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. The Motley Fool owns shares of and recommends Amazon and Facebook. The Motley Fool recommends the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. Fool contributor Cindy Dye owns shares of Amazon.

More on Tech Stocks

sale discount best price
Tech Stocks

2 Growth Stocks to Buy Every Time They Go on Sale (Like Now)

The right growth stocks are worth buying in almost any market, but they are especially attractive when they come with…

Read more »

stock data
Tech Stocks

Better Tech Trend for Investors: AI or Graphene?

Even though it’s the newer of two technologies, AI has outpaced graphene by a significant margin in the corporate world.…

Read more »

Man considering whether to sell or buy
Dividend Stocks

DND Stock: Buy, Sell, or Hold?

DND stock (TSX:DND) fell by 17% after producing earnings that once again fell below analyst estimates. But does that mean…

Read more »

Hand arranging wood block stacking as step stair with arrow up.
Tech Stocks

This Stock Is up 1,440%, But You Can Still Buy it

Constellation Software is a superb company that has made its long-term investors incredibly rich. And it's a good value today.

Read more »

Car, EV, electric vehicle
Tech Stocks

Tesla and Apple Have This 1 Trait in Common, and It’s Making Investors Rich

Tesla and Apple have a lot in common. But this one trait of building an ecosystem is boding well for…

Read more »

Upwards momentum
Tech Stocks

Growth Stocks: A Once-in-a-Decade Opportunity to Get Rich

Here’s a really attractive Canadian growth stock you can buy now and hold for the long term to see your…

Read more »

ETF chart stocks
Tech Stocks

You Don’t Have to Pick a Winner in AI Stocks: Here’s Why

Buy the sector instead of hoping for a moonshot.

Read more »

tsx today
Tech Stocks

TSX Today: What to Watch for in Stocks on Thursday, September 21

Overnight declines in commodity prices and fears of elevated interest rates for longer could drive TSX stocks downward at the…

Read more »